http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
채봉남 관동대학교 의과학연구소 2000 關東醫大學術誌 Vol.4 No.1
Under the influence of pregnancy, the β-cells of islet undergo major long term up-regulatory structural and functional changes in response to the increased demand for insulin. Histo-morphometry studies indicated that during pregnancy, islet mass was increased from 1.4-fold to 3-fold and insulin secretion was also increased. this study was focused the change of β -cells of pancreas in streptozotocin-induced diabetic pregnant rat. And we compare this result with β -cells of pancreas in normal pregnant rat. Sprague-Dawley rat divided four group: normal control, normal pregnancy, diabetes group, and diabetic pregnancy group. The rats of diabetes and diabetic pregnaney group were injected amount of 40 mg/kg of streptozotocin. All rats of four groups were tested oral glucose tolerance test on days 10 after streptozotocin injection and on days 18 of pregnancy. On 18 days of pregnancy, we observed islets of pancreas under the light microscopy with insulin immunohistochemical stain, and under the electron microscopy. Streptozotocin-induced diabetic rat had higher fasting glucose and integrated glucose area under the curve (GAUC), and lower fasting insulin level than normal rat(p〈0.05). But there was no significant difference of integrated areas under the insulin secretion response curve (IAUC). During pregnancy fasting glucose and GAUC were decreased insignificantly, but fasting insulin and IAUC were increased significantly in normal rat. But in diabetic rat, there were no significant difference in fasting insulin, glucose and GAUC during pregnancy except IAUC. Under the light microscopy, the area of β -cells by insulin immunohistochemistry was increased insignificantly in pregnant rat than in non-pregnant rat. The estimate far the increase in β -cells area during pregnancy in diabetic rat was 7.09% compare to 20.22% in normal rat. And the estimate for the increase in the number of islets in diabetic rat was 14.9% compare to 29.4% in normal rat. In conclusion, the area of β -cells and number of islets of pancreas in both normal and streptozotocin-induced diabetic rat during pregnancy were insignificantly increased. But the rate of increase in streptozotocin-induced diabetic rat was a half or one thirds to normal. So It was supposed that the structural change of endocrine pancreas during pregnancy was insufficient. In future, the mechanism of increase of endocrine pancreas mass during pregnancy was further studied. So it will indicate the way of treatment in pregnant diabetes and give a remedy of gestation diabetes.
일차성 골다공증 여성 환자에서 주기적인 pamidronate 정주 치료
채봉남,홍은경,이성규,정윤석,이관우,김현만 대한내분비학회 2001 Endocrinology and metabolism Vol.16 No.2
Background: Bisphosphonates are now well established as successful antiresorptive agents for the prevention and treatment of osteoporosis. We investigated the effect of cyclic intravenous treatment with an aminobisphosphonate, pamidronate in cases of primary osteoporosis. Methods: Eighteen patients with primary osteoporosis (bone mineral density BMD t-score <-2.5) received four courses of pamidronate (30 mg with 500 mL normal saline over 2 hours every 3 months). The serum biochemical parameters and bone turnover markers were measured before each treatment. The bone pain score, medication score, and the side effects were also monitored. BMD and simple spine X-ray were performed before and 1 year after of treatment. Results: BMD at the lumbar spine (L2-4) significantly increased from 0.798±0.110 g/㎠ to 0.860±0.107 g/㎠ after 1 year of treatment with pamidronate: by +8.3±9.4% of baseline. BMDs at the femoral neck, Ward s triangle and the trochanter also increased, but not significantly. Serum total alkaline phosphatase (p<0.05) and urine deoxypyridinoline/creatinine (p=0.069) decreased with treatment. Other bone turnover markers were unchanged. The bone pain score decreased significantly. None of the patients experienced a new fracture during treatment. The frequency of the side effects following the first infusion was 61.1% (a transient fever and myalgia with flu-like symptoms in 10 patients and mild phlebitis in 1 patient). However, only two patients complained of flu-like symptoms after second infusion, and no patient complained following the third infusion. Conclusion: Cyclic intravenous treatment of pamidronate every three months was effective in increasing BMD and in the decreasing bone turnover rate, and was relatively well tolerated in primary osteoporotic women.
다양한 대사적 이상을 나타낸 가족성 복합 고지혈증 가계 1예
김현만,이관우,채봉남,김윤정,이성규,홍은경,박지원,정윤석 대한내분비학회 1999 Endocrinology and metabolism Vol.14 No.2
Familial combined hyperlipidemia is one af the manogenic disorders frequently found in humans and is seen in 0.5~2% of the general populatian, accounting for at least 10% of persons with pemature atlmmcletusis. The distinguishing feature of familial combined hyperlipidemia, in camparison with other single-gene abnarmalities of lipoprotein metabolism, is that not all affected members have the same plasma lipid phenotype; some individuals have an elevation of cholesterol concentration alane(type IIa lipoprotein pattern), while some athers have an elevation of triglyceride concentration alone(type IV pattem), and still others have elevations of both values(type IIb pattem). In any one persan, the lipid phenotype can change as a result of dietary or drug treatment. Familial combined hyperlipidemia should be suspected in those subjects with moderate hypertriglyceridemia and/or moderate hypercholestaolemia (lipoprotein types IIa, Ilb, IV), especially when premature coronary heart disease is evident in the family histary. Low plasma HDL-cholesterol, obesity, insulin resistance and hyperuricemia are often . Family members affected by familial combined hyperlipidemia should be identified and be treated, since tbe condition is associated with premature caronary heart diasease. We have found one family of familial combined hyperlipidemia with one member(case 1) associated with insulin resistance, hyperuricemia and gout, and another member(case 2) associated with diabetes mellitus and infertiTity. (J Kor Soc Endocrinol 14:418-424, 1999)
김현만,이관우,채봉남,진윤미,김윤정,이성규,홍은경,임호영,정윤석,박소윤 대한내분비학회 1998 Endocrinology and metabolism Vol.13 No.3
Primary squamous cell carcinoma of the thyroid is rare, presenting much less than one percent of all primary thyroid malignancies. Most cases have been reported in elderly patients with a history of goiter. It is necessary to differentiate between primary squamous cell carcinoma and secondary involvement from other sites. Secondary involvement of the thyroid may be more amenable to palliation or cure. The treatment of choice in primary squamous cell carcinoma is radical surgery in resectable cases, but the squamous cell carcinoma behaves aggressively and carries a uniformly poor prognosis regardless of the treatment. We had an experience of a primary squamous cell carcinoma of the thyroid in two elderly patients. These patients presented a typical feature of a primary squamous cell carcinoma of the thyroid, which has been rarely reported in Korea (J Kor Soc Endocrinol 13:446-452, 1998).